Furthermore, RA patients who responded to anti-TNF-α therapy exhibited a transient increase in SARM that was not observed in non-responders, providing a possible mechanism by which TNF-α blockade additionally reduces IL-1β levels in RA patients. This evidence concerns the gene IL1B and rheumatoid arthritis.